Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery Of Novel Next-Generation Oxytocin Analogues At The American Chemistry Society Spring 2024 Meeting
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery Of Novel Next-Generation Oxytocin Analogues At The American Chemistry Society Spring 2024 Meeting
Tonix Pharmicals宣佈在美國化學學會2024年春季會議上發佈海報，描述新型下一代催產素類似物的發現
Four Phase 2 investigator-initiated studies of TNX-1900 (intranasal potentiated oxytocin) are ongoing for pediatric obesity, binge eating disorder, bone health in autism and social anxiety disorder
研究人員發起的四項針對兒科肥胖、暴飲暴食、自閉症骨骼健康和社交焦慮症的 TNX-1900（鼻內增強催產素）的二期研究正在進行中
TNX-2900 (intranasal potentiated oxytocin) is being developed under an IND as a treatment for Prader-Willi Syndrome, an Orphan Disease characterized by excessive eating
TNX-2900（鼻內強化催產素）是根據臨床試驗研究開發的，用於治療普拉德-威利綜合症，這是一種以過度進食爲特徵的孤兒病
TNX-1900 and TNX-2900 may serve as novel neuroendocrine treatments for certain pain, eating and endocrine disorders
TNX-1900 和 TNX-2900 可用作某些疼痛、進食和內分泌失調的新型神經內分泌治療方法
CHATHAM, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announces a poster presentation at...
新澤西州查塔姆，2024年3月21日（GLOBE NEWSWIRE）...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。